Referring to a polypeptide derived from il-2 selected from: (i) SEC ID N\ufffd1 comprising r38k mutations, f42i, y45n, e62l and e68v, (ii) SEC ID n\ufffd2 comprising r38k mutations, f42q, y45e and e68v, (iii) SEC ID n\ufffd3 comprising r38a mutations, f42i, y45n, e62l and e68v, (IV) SEC ID n\ufffd4 co No mutations r38k, f42k, y45r, e62l and e68v, (V) SEC ID n\ufffd5 with mutations r38k, f42q, y45e and e68v,(VI) SEC ID n\ufffd6 with mutations r38a, f42a, y45a and e62a. Also relates to a Pharmaceutical composition. These polypeptides are useful in the treatment of Cancer and chronic infectionsREFERIDA A UN POLIPEPTIDO DERIVADO DE LA IL-2 SELECCIONADO DE: (i) SEC ID N�1 QUE COMPRENDE MUTACIONES R38K, F42I, Y45N, E62L Y E68V, (ii) SEC ID N�2 QUE COMPRENDE MUTACIONES R38K, F42Q, Y45E Y E68V, (iii) SEC ID N�3 QUE COMPRENDE MUTACIONES R38A, F42I, Y45N, E62L Y E68V, (iv) SEC ID N�4 CON MUTACIONES R38K, F42K, Y45R, E62L Y E68V, (v) SEC ID N�5 CON MUTACIONES R38K, F42Q, Y45E Y E68V, (vi) SEC ID N�6 CON MUTACIONES R38A, F42A, Y45A Y E62A. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS POLIPEPTIDOS SON UTILES EN EL TRATAMIENTO DEL CANCER E INFECCIONES CRONICAS
